Core Insights - Cryoport, Inc. reported a total revenue of $57.6 million for Q2 2024, reflecting a 1% increase year-over-year and a 5.5% increase sequentially. For H1 2024, total revenue was $112.2 million, down from $119.8 million in H1 2023 [5][11] - The company has revised its full-year 2024 revenue guidance to a range of $225 million to $235 million, driven by anticipated sequential growth in Life Sciences Services and ongoing softness in Life Sciences Products [2][11] - Cryoport's net loss for Q2 2024 was $78.0 million, significantly higher than the net loss of $18.4 million in Q2 2023, primarily due to a $63.8 million impairment loss [8][9] Financial Performance - Life Sciences Services revenue for Q2 2024 was $38.0 million, up 8.1% year-over-year, while Life Sciences Products revenue was $19.6 million, down 10.4% year-over-year [5][6] - Gross margin for Q2 2024 was 43.7%, slightly up from 43.4% in Q2 2023. However, gross margin for Life Sciences Products decreased to 42.2% from 43.7% year-over-year [6][7] - Operating costs and expenses for Q2 2024 were $104.4 million, significantly higher than $43.1 million in Q2 2023, mainly due to the impairment loss [7][8] Business Segments - Revenue from commercial Cell & Gene Therapy increased by 51% year-over-year and 20% sequentially, indicating strong demand for these therapies [2][3] - BioStorage/BioServices revenue continued to grow, reflecting a double-digit increase year-over-year as new customers were added [3][5] - The company supported a total of 684 global clinical trials as of June 30, 2024, marking a net increase of 16 trials from the previous year [3][4] Cost Management and Outlook - Cryoport has implemented cost reduction initiatives expected to yield approximately $22 million in annualized savings by 2025, aiming for profitable growth and a return to positive adjusted EBITDA [2][11] - The company anticipates continued softness in demand for Life Sciences Products, with expectations of a market recovery in the broader life sciences industry, excluding China [3][11] - The company has authorized a repurchase program for up to $200 million of its common stock and/or convertible senior notes, indicating a strategic move to enhance shareholder value [10][11]

Core Viewpoint - Cryoport, Inc. has authorized a $200 million repurchase program for common stock and/or convertible senior notes, aimed at strengthening its balance sheet and maintaining liquidity for long-term growth [1][3]. Group 1: Repurchase Program Details - The 2024 Repurchase Program is effective from August 1, 2024, and will remain in effect until December 31, 2027 [1]. - The company plans to repurchase approximately $160 million of its 0.75% Convertible Senior Notes due in 2026 at an 11.5% discount to par value, resulting in a total repurchase price of $141.6 million plus accrued interest [1][2]. - Following the repurchase, the principal balance of the 2026 Notes will be reduced to approximately $186.2 million from an initial balance of $402.5 million [3]. Group 2: Company Overview - Cryoport, Inc. is a global leader in supply chain solutions for the life sciences, focusing on cell and gene therapies [5]. - The company provides a wide range of supply chain solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, biostorage, and cryogenic systems [5]. - Cryoport operates from its headquarters in Nashville, Tennessee, with over 50 global locations across 17 countries [6].

NASHVILLE, Tenn., July 23, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2024 on Tuesday, August 6, 2024 after U.S. markets close. Conference Call Information Date: Tuesday, August 6, 2024 Time: 5:00 p.m. ET Dial-in numbers: 1-800-717-1738 (U.S.), 1-646-307-1865 (International) Confirmation code:Request the " ...

Company Overview - CryoPort expects revenues to improve as the year progresses, driven primarily by the Life Sciences Products group [1] - The stock has recently seen a significant increase of 26.7%, closing at $7.03, following a period of 47.6% loss over the past four weeks [2] Stock Performance - The recent stock price increase was accompanied by higher-than-average trading volume, indicating strong investor interest [2] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting positive sentiment among analysts [2] Earnings Estimates - The consensus EPS estimate for CryoPort has remained unchanged over the last 30 days, indicating stability in earnings expectations [3] - Trends in earnings estimate revisions are correlated with near-term stock price movements, suggesting that future performance should be monitored closely [7] Industry Context - CryoPort operates within the Zacks Transportation - Services industry, which includes other companies like Despegar.com [6] - Despegar.com has a Zacks Rank of 1 (Strong Buy) and is expected to report a quarterly loss of $0.36 per share, reflecting a year-over-year change of +14.3% [4][5]

Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine Products NASHVILLE, Tenn. and YOKOHAMA, Japan, June 20, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnershi ...

Core Viewpoint - The Schall Law Firm is investigating Cryoport, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements or failed to disclose important information to investors [1]. Group 1 - The investigation is aimed at protecting the rights of investors who may have suffered losses due to the company's actions [1]. - Shareholders are encouraged to participate in the investigation if they have experienced financial losses [1]. - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [2].

Cryoport, Inc. (NASDAQ:CYRX) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Todd Fromer – Investor Relations-KCSA Strategic Communications Jerrell Shelton – Chief Executive Officer Mark Sawicki – Chief Scientific Officer Robert Stefanovich – Chief Financial Officer Thomas Heinzen – Vice President-Corporate Development and Investor Relations Conference Call Participants Matt Stanton – Jefferies Philip Song – Leerink Partners Lucas Baranowski – UBS David Larsen – BTIG Paul Knight ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 (St ...

®2024 CRYOPORT, INC. Condensed Consolidated Statements of Operations (unaudited) | 16 March 31, $ (18,895) $ 46 | 17 Cryoport Enabling the Future of Medicine Increased by 21 trials (net) over Q1 2023 | --- | --- | --- | --- | --- | --- | --- | --- | |---------|-----------|-----------|-----------|-----------|-----------|-----------|-----------| | 350 | 609 | 652 | 675 | 600 | 609 | 652 | 675 | | 300 | | | | 500 | | | | | 250 | | | | 400 | | | | | 200 | | | | 300 | | | | | 150 | | | | 200 | | | | | 100 | | | ...

Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results NASHVILLE, Tennessee, May 7, 2024, - Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for the three months ended March 31 (Q1), 2024. Jerrell Shelton, CEO of Cryoport, commented, "For the first quarter, we continued to experience a difficult environment globally. Our quarterly results were disappointing, particularly for our Life Sciences Products. Ho ...